Incyte Corporation Stock News

Incyte (INCY) news for Friday about a recent clinical trial failing to meet its endpoints has INCY stock taking a beating. The post Incyte News: INCY Stock Tumbles 10% on Experimental Drug Study Failu

An important clinical trial failed, reminding investors of the company's poor track record with its pipeline.

Incyte stock tumbled to a three-month low Friday amid a flurry of price-target cuts following the biotech company's late-stage failure in never-before-treated acute graft vs. host disease.

Incyte (INCY) fails to meet goals in the phase III study on itacitinib for the treatment of first-line acute GVHD.

Incyte stock crashed late Thursday after the biotech company's treatment for never-before-treated patients with graft vs. host disease, a transplant complication, failed in a study.

Incyte Corp. INCY, -1.55% shares fell more than 12% in after-hours trading Thursday after the company revealed that a phase-3 study of a drug failed to reach its goal.

Few biotech companies ever reach that valuation, and if they do, you should snap them up for your portfolio.

In the latest trading session, Incyte (INCY) closed at $88.39, marking a -0.44% move from the previous day.

Markets Take A Pause; Stock Setups Continue.

Incyte (INCY) outperforms the industry year to date on strong Jakafi sales.

Is (INCY) Outperforming Other Medical Stocks This Year?

Biotech Stock Outlook: M&A Activity Retains Growth Streak

Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Incyte is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

While value investors look for stocks that have become priced too low or high based on fundamental metrics such as earnings, revenue and debt, technical traders base their buys and sells off of recent